Financials
Financial year 2025
Orifarm Healthcare from Zaventem, company number BE0755731948, closed financial year 2025 with a result of € 197,513 after tax. For that financial year Orifarm Healthcare recorded revenue of € 31.3 million and equity of € 1.7 million. Compared with financial year 2024, the result moved from € 327,032 to € 197,513. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ 1.7 million
▲ 13% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 197,513
▼ 40% vs 2024
Profit after tax over the fiscal year.
€ 465,209
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.7 million.
People and assets in 2025
21.5
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 3.5 million
▲ 2% vs 2024
€ 164,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2.5 million
▲ 54% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 33 days on average.
€ 831,732
▼ 21% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | € 29,276,633 | € 31,311,569 | ▲ 7% |
| Gross margin | € 3,770,930 | € 4,293,402 | - | - | |
| Profit after taxes | € 319,984 | € 353,106 | € 327,032 | € 197,513 | ▼ 40% |
| Equity | € 815,543 | € 1,168,648 | € 1,495,681 | € 1,693,194 | ▲ 13% |
| Total debts | € 6,463,513 | € 7,283,663 | € 6,803,548 | € 4,743,165 | ▼ 30% |
| Cash | - | - | - | € 465,209 | |
| Retained profit | € 805,543 | € 1,158,648 | € 1,485,681 | € 1,683,194 | ▲ 13% |
| Bank debt | € 237,880 | € 2,109,196 | € 3,276,414 | € 0 | ▼ 100% |
| Balance sheet total | € 7,279,055 | € 8,452,311 | € 8,299,229 | € 6,496,360 | ▼ 22% |
| Employees (FTE) | 19.5 | 21.7 | 21.4 | 21.5 | ▲ 0.1 |
Key figures of Orifarm Healthcare, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Orifarm Healthcare?
What happened at Orifarm Healthcare in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 197,513 (▼ 40% vs 2024). Source: NBB ↗
- Nicki Lund Kristensen became a director. NBB
- Mads Fink Eriksen became a director. NBB
- Thomas Brandhof became a director. NBB
- New establishment in Zaventem. KBO
- Hans Carl Boegh-Soerensen became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 319,984 profit in 2022 to € 197,513 profit in 2025.
Paid € 581,628 in corporate taxes since 2022.
Best year ever: 2023, with € 353,106 profit.
On average € 197,900 of value added per employee in 2023.
A new publication or filing at Orifarm Healthcare? We notify you, reason included.
Follow Orifarm HealthcareDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Orifarm Healthcare are Thomas Brandhof, Nicki Lund Kristensen, Mads Fink Eriksen and Hans Carl Boegh-Soerensen. The shares are held by Orifarm Generics A/S B.O (100%).
Directors
According to the 2025 annual accounts
since 2024
since 2025
since 2025
since 2020
Shareholders
Orifarm Generics A/S B.O
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Da Vincilaan 7
1930 Zaventem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
All companies at this address →IQVIA Solutions Belgium
€ 33.1 million revenue · 2025
TAKEDA BELGIUM
€ 201.4 million revenue · 2025
IQVIA RDS & INTEGRATED SERVICES BELGIUM
€ 45.6 million revenue · 2025
IM ASSOCIATES
€ 3.1 million gross margin · 2025
IQVIA Cancer Research
€ 50,247 gross margin · 2025
+2 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0755.731.948
- VAT number
- BE 0755.731.948
- Registered office
- Da Vincilaan 7, 1930 Zaventem
- Names & denominations
- Orifarm Healthcare
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 6 October 2020
- Peppol
- Active · Active since 11 Jun 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen